Associated Papers
Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL.
Pavlova S et al.
Hemasphere, 2025
39840379 (PubMed )
Supplement: HEM3-9-e70065-s008.xlsx › Table_S7
Patient-derived tumor organoids mimic treatment-induced DNA damage response in glioblastoma.
Majc B et al.
Iscience, 2024
39252971 (PubMed )
Supplement: mmc2.xlsx › Sheet1
Mutations in the TP53, VEGFA, and CTH Genes as Key Molecular Markers for the Diagnosis of Glioblastoma.
Khalil SS et al.
Cureus, 2024
Targeted panel sequencing in the routine diagnosis of mature T- and NK-cell lymphomas: report of 128 cases from two German reference centers.
Böck J et al.
Frontiers in Oncology, 2023
37664054 (PubMed )
Supplement: Table_1.xlsx › Table_S2
Landscape of somatic alterations in large-scale solid tumors from an Asian population.
Wu L et al.
Nature Communications, 2022
35871175 (PubMed )
Supplement: 41467_2022_31780_MOESM6_ESM.xlsx › Supplementary_Data_4
TP53 Mutations Identified Using NGS Comprise the Overwhelming Majority of TP53 Disruptions in CLL: Results From a Multicentre Study.
Catherwood MA et al.
Frontiers in Oncology, 2022
35837095 (PubMed )
Supplement: Table_1.xlsx › Table_1
A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients.
Zhang Y et al.
Scientific Reports, 2021
33432021 (PubMed )
Supplement: 41598_2020_79694_MOESM2_ESM.xlsx › Sheet1
Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
Jovelet C et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
26758560 (PubMed )
Supplement: 10780432ccr152470-sup-156650_1_supp_3254814_ny79rd.xlsx › AF_T-P
Select a paper to view details